Език: EN EN
← Назад към резултатите
Набира участници Не е приложимо NCT06088212

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Не е приложима фаза (напр. обсервационно)
Заболявания: Heart Failure Cognitive Impairment Dementia Left Ventricular Dysfunction Cognitive Change Cognitive Decline

Спонсор: Baker Heart and Diabetes Institute

Налично на: БГ
Обобщение
This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.
Кой може да участва
Inclusion Criteria: 1. Hospitalised with HF as primary or secondary diagnosis. 2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge. Exclusion Criteria: 1. Unable to provide written consent; requiring palliative care; or participating in another RCT 2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" CI, any patients with a repeated MoCA\>25 at 2 weeks post-discharge will be excluded. 3. Terminal illness (eg. cancer) that may influence 12-month prognosis.
Места на провеждане 1
Австралия (1)
Menzies Institute for Medical Research
Hobart , Tasmania
Технически детайли
Статус
Набира участници
Фаза
Не е приложимо
Вид изследване
INTERVENTIONAL
Пол
Мъже и жени
Минимална възраст
18 Years
Здрави доброволци
Не
Начална дата
01.07.2024
Крайна дата
01.07.2026
Регистрационен номер
NCT06088212
Източник
anzctr
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.